We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Hutchison China MediTech
2020 set to be the “breakthrough” yearHutchison China MediTech
$110m raised through ADS public offerHutchison China MediTech
SANET-p trial stopped early for efficacyFutura Medical
Fund raise of £3.25m, at 8p a share, confirmed at EGMScancell
Third collaboration for AvidiMab platformMaxCyte
Increasingly in demand as partner of choiceNexstim
Licensing discussions with academic centre endMereo BioPharma
Additional ASTEROID data supports progressionMereo BioPharma
Oncologie takes global licence to NaviBerGenBio
AXL opportunities opening up